Clinical trials: Non-small Cell Lung Cancer Stage III
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer
Phase II trial to study the effectiveness of bortezomib in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00040768
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Lung Cancer
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer, Nsclc, NSCLC Stage II
- Trial name
- NCT03999710
- Testing
- Radiation Therapy, Durvalumab
- Where
- 9 sites in United States
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Squamous Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cancer
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen
The purpose of this study is to provide treatment with nivolumab, a fully human monoclonal antibody, to subjects who have relapsed after treatment with a minimum of 1 prior systemic treatment for advanced or metastatic squamous…
- Trial name
- CheckMate 169 (NCT02475382)
- Testing
- Nivolumab
- Where
- 50 sites in Brazil, Canada
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
The purpose of this multi-center Phase II trial is to examine the impact of pemetrexed/carboplatin in the preoperative treatment of patients with select stage IB, II,and III non-squamous NSCLC.
- Trial name
- NCT00906282
- Testing
- Pemetrexed, Carboplatin
- Where
- 12 sites in United States
- Volunteers
- 46 people
- Sponsor
- SCRI Development Innovations, LLC
Lung Cancer Non-small Cell Stage IV
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
This is a phase III , randomized, double-blinded, multicenter clinical study to compare efficacy and safety of AK105 (Anti-PD1 antibody) combined with Carboplatin and Pemetrexed vs Placebo combined with Carboplatin and Pemetrexed…
- Trial name
- NCT03866980
- Testing
- AK105, carboplatin, pemetrexed
- Where
- 2 sites in China
- Volunteers
- 164 people
- Sponsor
- Akeso
NSCLC
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
A randomized, double-blind, positive controlled phase III study to evaluate the efficacy and safety of BPI-7711 capsule in locally advanced or recurrent/metastatic treatment-naïve non-small cell lung cancer patients with EGFR…
- Trial name
- NCT03866499
- Testing
- BPI-7711, Gefitinib
- Where
- 3 sites in China
- Volunteers
- 369 people
- Sponsor
- Beta Pharma Shanghai
Carcinoma，Non-Small-Cell Lung
A Prospective Multi-center Phase III Randomized Controlled Trial
The purpose of this study is to investigate the PFS, ORR, OS and overall toxicity value（OTV）on advanced adenocarcinoma treated with nedaplatin or cisplatin combined with pemetrexed.
- Trial name
- NACA (NCT02607592)
- Testing
- cisplatin and pemetrexed, nedaplatin+pemetrexed
- Where
- China
- Volunteers
- 293 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
Background: For patients with resectable stage III-N2b non-small cell lung cancer (NSCLC), optimal perioperative treatment strategies remain an area of active investigation.
- Conditions
- Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging, Lymphatic Metastasis
- Trial name
- NCT07538193
- Testing
- Iparomlimab and Tuvonralimab combined with Platinum-Based Chemotherapy (Pemetrexed/Carboplatin for Non-squamous; Nab-paclitaxel/Carboplatin for Squamous)
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tang-Du Hospital
Stage IIIb Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
To determine whether tariquidar + first-line single agent vinorelbine chemotherapy in patients with Stage IIIb/IV NSCLC will, with an acceptable safety profile, significantly improve overall survival compared with placebo +…
- Trial name
- NCT00042315
- Testing
- Chemotherapy, tariquidar + vinorelbine
- Volunteers
- 490 people
- Sponsor
- QLT Inc.
Lung Cancer
Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin, irinotecan, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00449020
- Testing
- Carboplatin, Docetaxel, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Miami
Non Small Cell Lung Cancer, Stage III Lung Cancer
Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
This study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery.
- Trial name
- RESCUE (NCT06878274)
- Testing
- Post-operative radiotherapy
- Where
- Canada
- Volunteers
- 118 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Lung Cancer
Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00022646
- Testing
- gemcitabine hydrochloride, pemetrexed disodium
- Where
- 22 sites in United States
- Volunteers
- 157 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003117
- Testing
- carboplatin, paclitaxel
- Where
- 35 sites in United States
- Volunteers
- 584 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer Stage III
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Primary Evaluate safety and toxicity of AN0025 in both the consolidative setting (after chemoradiation) and in the concurrent setting (during chemoradiation) Evaluate efficacy by progression-free survival (PFS), objective…
- Trial name
- NCT05358691
- Testing
- AN0025
- Where
- United States
- Sponsor
- Rutgers, The State University of New Jersey
Lung Cancer
Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Vinorelbine is currently the standard treatment for elderly patients with advanced non-small cell lung cancer (NSCLC). Docetaxel has also shown promising results against elderly patients in phase II studies.
- Trial name
- NCT00148291
- Testing
- Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.
- Volunteers
- 180 people
- Sponsor
- West Japan Thoracic Oncology Group
Carcinoma, Non-Small-Cell Lung
A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients
The vaccine contains humanized recombinant antigen (Epithelial Growth Factor) and an adjuvant. The antibodies induced by vaccination will react with circulating EGF leading to removal of EGF from the circulation.
- Trial name
- NSCLC (NCT01444118)
- Testing
- Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)
- Where
- United Kingdom
- Sponsor
- Bioven Europe
Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
The goal of this clinical trial is to compare the amount of study drug in patients' blood to confirm that SB27 works in the same way as EU and US sourced Keytruda in early or locally advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT06268613
- Testing
- SB27, EU sourced Keytruda, US sourced Keytruda
- Where
- 24 sites in Poland, South Korea and 2 more
- Volunteers
- 163 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
This phase II clinical trial studies how well combining different regimens of chemotherapy and gefitinib with radiation therapy work in treating patients with stage III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00040794
- Testing
- paclitaxel, carboplatin, gefitinib
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.
- Trial name
- LungTIME-C01 (NCT05549037)
- Testing
- Pembrolizumab, Sintilimab
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Hunan Province Tumor Hospital
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
This phase I trial studies how well talactoferrin works in treating patients with relapsed or refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01528137
- Testing
- talactoferrin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University